|
US20030157161A1
(en)
*
|
2001-05-01 |
2003-08-21 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
|
US20020192280A1
(en)
*
|
2001-05-01 |
2002-12-19 |
Angiotech Pharmaceuticals, Inc. |
Compositions and methods for treating inflammatory conditions utilizing protein or polysaccharide containing anti-microtubule agents
|
|
US7354574B2
(en)
|
2002-11-07 |
2008-04-08 |
Advanced Ocular Systems Limited |
Treatment of ocular disease
|
|
US7326256B2
(en)
|
2002-12-06 |
2008-02-05 |
L'ORéAL S.A. |
Composition for the oxidation dyeing of keratin fibers, comprising at least one non-oxyalkenylated fatty alcohol, at least one oxidation dye, at least one associative polymer, and at least one amide of an alkanolamine and a C14-C30 fatty acid
|
|
FR2848106B1
(fr)
*
|
2002-12-06 |
2006-11-17 |
Oreal |
Composition de teinture pour fibres keratiniques comprenant un alcool gras non oxyalkylene, un colorant d'oxydation, un polymere associatif et un amide d'une alcanolamine et d'un acide gras en c14-c30.
|
|
JP2004262777A
(ja)
*
|
2003-02-27 |
2004-09-24 |
Shiseido Co Ltd |
アセチル化ヒアルロン酸含有眼用医薬組成物
|
|
US20050196370A1
(en)
*
|
2003-03-18 |
2005-09-08 |
Zhi-Jian Yu |
Stable ophthalmic oil-in-water emulsions with sodium hyaluronate for alleviating dry eye
|
|
WO2004096261A1
(es)
*
|
2003-05-02 |
2004-11-11 |
Arturo Jimenez Bayardo |
Metodo para preparar una solucion acuosa de ciclosporina-a y solucion acuosa resultante
|
|
US7947295B2
(en)
*
|
2003-06-13 |
2011-05-24 |
Alcon, Inc. |
Ophthalmic compositions containing a synergistic combination of two polymers
|
|
US7083802B2
(en)
|
2003-07-31 |
2006-08-01 |
Advanced Ocular Systems Limited |
Treatment of ocular disease
|
|
CA2539324A1
(en)
|
2003-09-18 |
2005-03-31 |
Macusight, Inc. |
Transscleral delivery
|
|
US7087237B2
(en)
|
2003-09-19 |
2006-08-08 |
Advanced Ocular Systems Limited |
Ocular solutions
|
|
US7083803B2
(en)
|
2003-09-19 |
2006-08-01 |
Advanced Ocular Systems Limited |
Ocular solutions
|
|
EP1706095B1
(en)
*
|
2004-01-20 |
2008-12-24 |
Allergan, Inc. |
Compositions for localized therapy of the eye, comprising preferably triamcinolone acetonide and hyaluronic acid
|
|
US7135455B2
(en)
*
|
2004-11-15 |
2006-11-14 |
Allergan, Inc |
Methods for the therapeutic use of cyclosporine components
|
|
WO2006067608A1
(en)
*
|
2004-12-22 |
2006-06-29 |
Laboratoire Medidom S.A. |
Aqueous formulations based on sodium hyaluronate for parenteral use
|
|
JP4974903B2
(ja)
|
2005-02-09 |
2012-07-11 |
参天製薬株式会社 |
疾患または状態を処置するための液体処方物
|
|
US8663639B2
(en)
|
2005-02-09 |
2014-03-04 |
Santen Pharmaceutical Co., Ltd. |
Formulations for treating ocular diseases and conditions
|
|
CN100478025C
(zh)
*
|
2005-03-25 |
2009-04-15 |
中国科学院上海药物研究所 |
一种环孢菌素a眼用微乳制剂及其制备方法
|
|
CA2611909C
(en)
*
|
2005-07-01 |
2014-01-07 |
Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. |
Composition for treatment of corneal disease
|
|
US20070014760A1
(en)
*
|
2005-07-18 |
2007-01-18 |
Peyman Gholam A |
Enhanced recovery following ocular surgery
|
|
AU2006270041B2
(en)
|
2005-07-18 |
2011-08-18 |
Minu, Llc |
Enhanced ocular neuroprotection/neurostimulation
|
|
US7501393B2
(en)
*
|
2005-07-27 |
2009-03-10 |
Allergan, Inc. |
Pharmaceutical compositions comprising cyclosporins
|
|
CA2625532C
(en)
|
2005-10-12 |
2013-10-01 |
Seikagaku Corporation |
Agent for applying to mucosa containing a hydrophobic group binding type glycosaminoglycan
|
|
US9839667B2
(en)
|
2005-10-14 |
2017-12-12 |
Allergan, Inc. |
Prevention and treatment of ocular side effects with a cyclosporin
|
|
US7745400B2
(en)
*
|
2005-10-14 |
2010-06-29 |
Gregg Feinerman |
Prevention and treatment of ocular side effects with a cyclosporin
|
|
WO2007056457A2
(en)
*
|
2005-11-09 |
2007-05-18 |
Combinatorx, Incorporated |
Methods, compositions, and kits for the treatment of medical conditions
|
|
EP2455382B1
(en)
|
2005-12-13 |
2016-10-26 |
Incyte Holdings Corporation |
Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
|
|
WO2007092620A2
(en)
|
2006-02-09 |
2007-08-16 |
Macusight, Inc. |
Stable formulations, and methods of their preparation and use
|
|
US7655625B2
(en)
|
2006-02-13 |
2010-02-02 |
Allergan, Inc. |
Methods of treating blepharospasm using cyclosporine components
|
|
US20070212420A1
(en)
*
|
2006-03-10 |
2007-09-13 |
Bausch & Lomb Incorporated |
Pharmaceutical formulations comprising polyanionic materials and zinc-based preservatives
|
|
PL2001466T3
(pl)
|
2006-03-23 |
2016-06-30 |
Santen Pharmaceutical Co Ltd |
Rapamycyna w małej dawce do leczenia chorób związanych z przepuszczalnością naczyń
|
|
EP2043628A4
(en)
*
|
2006-06-27 |
2009-11-25 |
Riolan Technologies Inc |
ULTRAVIOLET ABSORBENT OPHTHALMIC COMPOSITIONS
|
|
AU2016203191B2
(en)
*
|
2006-07-25 |
2018-03-01 |
Allergan, Inc. |
Cyclosporin compositions
|
|
US9561178B2
(en)
*
|
2006-07-25 |
2017-02-07 |
Allergan, Inc. |
Cyclosporin compositions
|
|
WO2008035246A2
(en)
|
2006-07-28 |
2008-03-27 |
Novagali Pharma Sa |
Compositions containing quaternary ammonium compounds
|
|
CN101896160A
(zh)
*
|
2006-10-17 |
2010-11-24 |
阿勒根公司 |
环胞菌素组合物
|
|
WO2008119500A1
(en)
*
|
2007-03-30 |
2008-10-09 |
Fovea Pharmaceuticals Sa |
Methods for treating neovascular ocular diseases
|
|
EP3070090B1
(en)
|
2007-06-13 |
2018-12-12 |
Incyte Holdings Corporation |
Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
|
|
NZ584275A
(en)
*
|
2007-10-08 |
2012-06-29 |
Fovea Pharmaceuticals |
Aqueous cyclosporine ophthalmic formulations
|
|
ES2667945T3
(es)
|
2007-10-08 |
2018-05-16 |
Aurinia Pharmaceuticals Inc. |
Composiciones oftálmicas que comprenden inhibidores de calcineurina o Inhibidores de mTOR
|
|
US20100016219A1
(en)
*
|
2008-07-19 |
2010-01-21 |
Jerry Zhang |
Ophthalmic compositions containing solubilized cyclosporin
|
|
CL2009001884A1
(es)
*
|
2008-10-02 |
2010-05-14 |
Incyte Holdings Corp |
Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
|
|
GB0904423D0
(en)
*
|
2009-03-14 |
2009-04-29 |
Univ Strathclyde |
Improving the solubility of chemicals
|
|
SG176111A1
(en)
|
2009-05-22 |
2011-12-29 |
Incyte Corp |
3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
|
|
JP5775070B2
(ja)
|
2009-05-22 |
2015-09-09 |
インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ |
ヤヌスキナーゼ阻害剤としてのピラゾール−４−イル−ピロロ［２，３−ｄ］ピリミジンおよびピロール−３−イル−ピロロ［２，３−ｄ］ピリミジンのＮ−（ヘテロ）アリール−ピロリジン誘導体
|
|
EP2440185B1
(en)
*
|
2009-06-09 |
2015-04-08 |
Aurinia Pharmaceuticals Inc. |
Topical drug delivery systems for ophthalmic use
|
|
AR078012A1
(es)
|
2009-09-01 |
2011-10-05 |
Incyte Corp |
Derivados heterociclicos de las pirazol-4-il- pirrolo (2,3-d) pirimidinas como inhibidores de la quinasa janus
|
|
PT3354652T
(pt)
|
2010-03-10 |
2020-07-20 |
Incyte Holdings Corp |
Derivados de piperidin-4-ilazetidina como inibidores de jak1
|
|
RS54824B1
(sr)
|
2010-05-21 |
2016-10-31 |
Incyte Holdings Corp |
Topikalna formulacija za inhibiciju jak-a
|
|
WO2012068440A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
|
|
CA2818542A1
(en)
|
2010-11-19 |
2012-05-24 |
Incyte Corporation |
Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
|
|
MY165963A
(en)
|
2011-06-20 |
2018-05-18 |
Incyte Holdings Corp |
Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
|
|
TW201313721A
(zh)
|
2011-08-18 |
2013-04-01 |
Incyte Corp |
作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
|
|
UA111854C2
(uk)
|
2011-09-07 |
2016-06-24 |
Інсайт Холдінгс Корпорейшн |
Способи і проміжні сполуки для отримання інгібіторів jak
|
|
RU2630970C2
(ru)
*
|
2011-11-15 |
2017-09-15 |
Аллерган, Инк. |
Автоклавируемые взвеси циклоспорина а формы 2
|
|
RU2639393C2
(ru)
*
|
2011-11-15 |
2017-12-21 |
Аллерган, Инк. |
Состав пролонгированного действия циклоспорина формы 2
|
|
FR2988297B1
(fr)
*
|
2012-03-22 |
2014-03-28 |
Thea Lab |
Solution ophtalmique aqueuse a base de ciclosporine a sans conservateur
|
|
TW201406761A
(zh)
|
2012-05-18 |
2014-02-16 |
Incyte Corp |
做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
|
|
CN113384546A
(zh)
|
2012-11-15 |
2021-09-14 |
因赛特公司 |
鲁索利替尼的缓释剂型
|
|
WO2014138168A1
(en)
|
2013-03-06 |
2014-09-12 |
Incyte Corporation |
Processes and intermediates for making a jak inhibitor
|
|
EP4137139A1
(en)
|
2013-07-10 |
2023-02-22 |
Matrix Biology Institute |
Compositions of hyaluronan with high elasticity and uses thereof
|
|
SG10201801069QA
(en)
|
2013-08-07 |
2018-03-28 |
Incyte Corp |
Sustained release dosage forms for a jak1 inhibitor
|
|
US9498467B2
(en)
|
2014-05-30 |
2016-11-22 |
Incyte Corporation |
Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
|
|
MY196111A
(en)
*
|
2014-07-18 |
2023-03-15 |
Allergan Inc |
Suspension Compositions of Cyclosporin a for Subconjunctival and Periocular Injection
|
|
PL3352766T3
(pl)
|
2015-09-24 |
2021-08-02 |
Matrix Biology Institute |
Kompozycie z hialuronanem o dużej elastyczności i sposoby ich użycia
|
|
KR101635915B1
(ko)
*
|
2016-02-15 |
2016-07-04 |
삼천당제약주식회사 |
사이클로스포린과 히알루론산 또는 이의 염을 포함하는 수용액 형태의 안과용 조성물
|
|
US20190240251A1
(en)
*
|
2016-10-14 |
2019-08-08 |
i.com medical GmbH |
Method for establishing, restoring, and preserving homeostasis of the ocular surface
|
|
US20190224275A1
(en)
|
2017-05-12 |
2019-07-25 |
Aurinia Pharmaceuticals Inc. |
Protocol for treatment of lupus nephritis
|
|
WO2019060696A1
(en)
*
|
2017-09-25 |
2019-03-28 |
Surface Pharmaceuticals, Inc. |
OPTHALMIC PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THE TREATMENT OF OCULAR SURFACE DISEASE
|
|
AR113922A1
(es)
|
2017-12-08 |
2020-07-01 |
Incyte Corp |
Terapia de combinación de dosis baja para el tratamiento de neoplasias mieloproliferativas
|
|
EA202091830A1
(ru)
|
2018-01-30 |
2020-12-29 |
Инсайт Корпорейшн |
Способы и промежуточные соединения для получения ингибитора jak
|
|
EP3773330B1
(en)
*
|
2018-03-29 |
2025-03-05 |
Mati Therapeutics Inc. |
Ophthalmic drug sustained release formulation and uses for dry eye syndrome treatment
|
|
MD3773593T2
(ro)
|
2018-03-30 |
2024-10-31 |
Incyte Corp |
Tratament hidradenitei supurative utilizând inhibitori ai JAK
|
|
CA3124945A1
(en)
|
2018-12-27 |
2020-07-02 |
Surface Ophthalmics, Inc. |
Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
|
|
WO2021008668A1
(en)
|
2019-07-12 |
2021-01-21 |
Pharmathen S.A. |
Preservative free pharmaceutical composition for ophthalmic administration containing cyclosporine
|
|
CN115038443A
(zh)
|
2019-11-22 |
2022-09-09 |
因西特公司 |
包含alk2抑制剂和jak2抑制剂的组合疗法
|
|
EP3988122A4
(en)
*
|
2019-12-17 |
2023-01-18 |
Yizhou (Shanghai) Biological Medicine Co, Ltd. |
USE OF TRANSTHYRETIN FOR INTRODUCTION TO THE EYE AND MAKING DROPS
|
|
US20210290527A1
(en)
*
|
2020-03-23 |
2021-09-23 |
Eyegate Pharmaceuticals, Inc. |
Compositions and Methods for Treatment of Ocular Conditions
|
|
GR1010012B
(el)
|
2020-05-12 |
2021-05-27 |
Φαρματεν Α.Β.Ε.Ε. |
Φαρμακευτικο σκευασμα ελευθερο συντηρητικου για οφθαλμικη χορηγηση περιεχον κυκλοσπορινη
|
|
US11833155B2
(en)
|
2020-06-03 |
2023-12-05 |
Incyte Corporation |
Combination therapy for treatment of myeloproliferative neoplasms
|
|
US12102632B2
(en)
|
2020-08-26 |
2024-10-01 |
Somerset Therapeutics, Llc |
Quinolone dispersions
|
|
US11510930B2
(en)
*
|
2020-08-26 |
2022-11-29 |
Somerset Therapeutics, Llc |
Gatifloxacin, prednisolone, and bromfenac compositions and methods
|
|
US12440510B2
(en)
|
2021-05-10 |
2025-10-14 |
Surface Ophthalmics, Inc. |
Use of chondroitin sulfate for relieving ocular pain
|
|
US12310981B2
(en)
|
2021-05-10 |
2025-05-27 |
Surface Ophthalmics, Inc. |
Use of chondroitin sulfate for relieving ocular pain
|
|
US20250360217A1
(en)
*
|
2022-07-20 |
2025-11-27 |
Asahi Kasei Kabushiki Kaisha |
Hyaluronic acid derivative pharmaceutical composition and method of producing pharmaceutical composition
|